EUVIMEDEUVIMED entdecken
Crossref

Farrerol alleviates hepatic ischemia-reperfusion injury by regulating the CD14/MyD88/NF-κB signaling pathway

Hongliang Liang, Jiansen Lu, Hao Pan, Tian Han, Yining Chen, Weiye Zhang, Shiyu Liu, Zhipeng Wang, Wen Hou, Zhongyang Shen

International Immunopharmacology · 2026-11 · 189 · 117442

DOI: 10.1016/j.intimp.2026.117442 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026-11. Verfasst von Hongliang Liang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Organ Transplant Research Center, Institute of Transplantation Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China. Hauptthemen laut MEDLINE: Reperfusion Injury, Liver, Anti-Inflammatory Agents, Liver Diseases. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Natural Science Foundation of Tianjin Science and Technology Correspondent Project, National Key Scientific Instrument and Equipment Development Projects of China, Natural Science Foundation of Tianjin Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatic ischemia-reperfusion injury (HIRI) remains a critical complication in liver surgery with limited pharmacological options, and while Farrerol (FA), a natural dihydroflavone, has shown protective effects in other organ IR models, its role in HIRI has never been explored. In this study, we established a murine model of 70% HIRI models and found that intravenous administration of FA (10 and 20 mg/kg) at the onset of reperfusion significantly attenuated HIRI, as evidenced by reduced serum ALT/AST levels, improved histopathology, decreased hepatocyte apoptosis, mitigated oxidative stress, and downregulated inflammatory cytokine expression. To uncover the underlying mechanism, we performed transcriptomic analysis of liver tissues, which unexpectedly identified CD14 as a key target and revealed that FA markedly suppressed the MyD88/NF-κB signaling pathway. Mechanistic validation in LPS-stimulated RAW264.7 macrophages confirmed that FA dose-dependently inhibited M1 polarization and inflammatory responses. Crucially, CD14 overexpression in macrophages largely abrogated the anti‑inflammatory effects of FA. By contrast, CD14 silencing mimicked FA‑mediated suppression of NF‑κB activation and cytokine release, and FA treatment exerted no further inhibitory effects in CD14‑silenced macrophages. Collectively, our findings demonstrate for the first time that FA alleviates HIRI by downregulating macrophage CD14 expression, thereby inhibiting the downstream MyD88/NF-κB pathway and its associated inflammatory cascade, positioning FA as a promising therapeutic candidate and highlighting CD14 as a viable target for HIRI intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reperfusion InjuryLiverAnti-Inflammatory AgentsLiver DiseasesAnimalsMyeloid Differentiation Factor 88NF-kappa BSignal TransductionMiceLipopolysaccharide ReceptorsMaleRAW 264.7 CellsMice, Inbred C57BLMacrophagesDisease Models, AnimalCytokinesHumans

Stichwörter der Autor:innen

CD14FarrerolHepatic ischemia-reperfusion injuryMacrophage polarizationNF-κB pathway

Substanzen

Myeloid Differentiation Factor 88NF-kappa BLipopolysaccharide ReceptorsMyd88 protein, mouseCd14 protein, mouseAnti-Inflammatory AgentsCytokines

Autor:innen und Institutionen

  • Tianjin Organ Transplant Research Center, Institute of Transplantation Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China.
  • Tianjin Organ Transplant Research Center, Institute of Transplantation Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China; School of Medicine, Nankai University, Tianjin, China.
  • School of Medicine, Nankai University, Tianjin, China.
  • Tianjin Organ Transplant Research Center, Institute of Transplantation Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China. Electronic address: houwen@nankai.edu.cn.
  • Tianjin Organ Transplant Research Center, Institute of Transplantation Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China; School of Medicine, Nankai University, Tianjin, China. Electronic addre…

Förderung

  • Natural Science Foundation of Tianjin Science and Technology Correspondent Project
  • National Key Scientific Instrument and Equipment Development Projects of China
  • Natural Science Foundation of Tianjin Municipality
  • Tianjin Municipal Health Commission

Zitieren

APA

Liang, H., Lu, J., Pan, H., Han, T., Chen, Y., Zhang, W., Liu, S., Wang, Z., Hou, W., & Shen, Z. (2026). Farrerol alleviates hepatic ischemia-reperfusion injury by regulating the CD14/MyD88/NF-κB signaling pathway. International Immunopharmacology, 189, 117442. https://doi.org/10.1016/j.intimp.2026.117442

Vancouver

Liang H, Lu J, Pan H, Han T, Chen Y, Zhang W, et al. Farrerol alleviates hepatic ischemia-reperfusion injury by regulating the CD14/MyD88/NF-κB signaling pathway. International Immunopharmacology. 2026;189:117442. doi:10.1016/j.intimp.2026.117442

BibTeX
@article{Liang2026,
  author = {Liang, Hongliang and Lu, Jiansen and Pan, Hao and Han, Tian and Chen, Yining and Zhang, Weiye and Liu, Shiyu and Wang, Zhipeng and Hou, Wen and Shen, Zhongyang},
  title = {Farrerol alleviates hepatic ischemia-reperfusion injury by regulating the CD14/MyD88/NF-κB signaling pathway},
  journal = {International Immunopharmacology},
  year = {2026},
  volume = {189},
  pages = {117442},
  doi = {10.1016/j.intimp.2026.117442}
}
Kostenlos starten →